A Phase 3b, Open-Label Study of Crinecerfont to Evaluate Androgen Reduction and Related Outcomes in Adults With Classic Congenital Adrenal Hyperplasia

Status

Not yet recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-524282-24-00

Enrollment

Registered

2026-07-23

Start date

Unknown

Completion date

Unknown

Last updated

2026-07-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Classic Congenital Adrenal Hyperplasia (CAH)

Brief summary

Change from baseline in pre-GC serum androstenedione at Week 24.

Detailed description

Not applicable

Interventions

DRUGNBI-74788

Eligibility

Sex/Gender

All

Age

18 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
Change from baseline in pre-GC serum androstenedione at Week 24.	—

Secondary

Measure	Time frame
Not applicable	—

Outcome results

None listed

Source: EU CTIS · Data processed: Jul 25, 2026